Jump to main content
)

Press Releases

Press Releases


Agreement with uniQure on Haemophilia Gene Therapy
06 May 2021

• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
02 Apr 2021

Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints to show efficacy in adults hospitalized with COVID-19

CSL Australia Dispatches COVID 19 Vaccine
24 Mar 2021

CSL Dispatches First Australian Made Doses of the AstraZeneca COVID 19 Vaccine.

Read more news releases on our global corporate website here.

CSL Behring Media Contact

Stephanie Fuchs
Marburg, Deutschland
Mobile: +49 (0)151 58438860
stephanie.fuchs@cslbehring.com